Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H28N2O3.C4H4O4 |
Molecular Weight | 508.5629 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CCC1=CC2=C(CC(C2)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4)C=C1CC
InChI
InChIKey=IREJFXIHXRZFER-PCBAQXHCSA-N
InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16022567
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514 |
76.0 nM [Ki] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218 |
91.4 nM [Ki] | ||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514 |
76.0 nM [Ki] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218 |
91.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ARCAPTA NEOHALER Approved UseUTIBRONTM NEOHALER® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use: UTIBRON NEOHALER is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.2) Launch Date2011 |
|||
Primary | ARCAPTA Approved UseINDICATIONS AND USAGE. ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ARCAPTA NEOHALER is NOT indicated for asthma. Launch Date2011 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
528 pg/mL |
110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
339 pg/mL |
110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.206 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.518 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.299 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.697 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2750 pg × h/mL |
110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
907 pg × h/mL |
110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.974 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.51 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
116 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
118 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Disc. AE: Dyspnea, Wheezing... AEs leading to discontinuation/dose reduction: Dyspnea (serious, 1 patient) Sources: Wheezing (serious, 1 patient) Asthma (moderate, 1 patient) Cough (moderate, 1 patient) |
75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma Sources: |
Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Asthma | moderate, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Cough | moderate, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Dyspnea | serious, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Wheezing | serious, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Adverse event | grade 5 | 75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000PharmR.pdf#page=46 Page: 46.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. | 2005 Jul |
|
Gateways to clinical trials. | 2006 May |
|
Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. | 2007 |
|
Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. | 2007 Oct |
|
New approaches to managing asthma: a US perspective. | 2008 Apr |
|
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. | 2008 Dec |
|
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. | 2008 Jul |
|
A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. | 2008 Nov-Dec |
|
Gateways to clinical trials. | 2008 Oct |
|
Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist. | 2009 Mar 12 |
|
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. | 2009 Oct |
|
Gateways to clinical trials. | 2009 Sep |
|
[Efficacy and safety of indacaterol - new long-acting beta(2) agonist]. | 2010 |
|
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. | 2010 Dec |
|
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. | 2010 Dec |
|
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. | 2010 Dec |
|
Indacaterol: in chronic obstructive pulmonary disease. | 2010 Dec 3 |
|
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. | 2010 Jun |
|
Indacaterol for chronic obstructive pulmonary disease (COPD). | 2010 Mar |
|
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. | 2010 Mar 8 |
|
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. | 2010 May 13 |
|
[Indacaterol is a new once-daily beta2-agonist for treatment of COPD]. | 2010 Nov 22 |
|
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. | 2010 Oct 29 |
|
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial. | 2010 Sep |
|
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. | 2010 Sep 7 |
|
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. | 2012 Oct 1 |
|
Metabolism and pharmacokinetics of indacaterol in humans. | 2012 Sep |
|
Emerging Therapeutic Options for the Management of COPD. | 2013 |
|
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal. | 2016 Oct |
|
An update on LAMA/LABA combinations for COPD. | 2017 Jan |
|
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study. | 2017 Jan 11 |
Sample Use Guides
The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16022567
In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
OSLIF BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
HIROBRIZ BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ULUNAR BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ONBREZ BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1114325
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | RxNorm | ||
|
UU-172
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
2JEC1ITX7R
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
9827599
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
753498-25-8
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
100000092727
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
68573
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
DBSALT000101
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
435273-74-8
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
m6240
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1095777
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
SUB30300
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY | |||
|
C81640
Created by
admin on Fri Dec 15 16:23:33 GMT 2023 , Edited by admin on Fri Dec 15 16:23:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD